Poolbeg Pharma PLC (LSE:POLB) Financings

Poolbeg Pharma PLC

Financings

RaiseDateIn US dollars
Private placement of new ordinary shares
Closed: £3.5M raised · GBX 6 a share · OAK Securities
Dealers: OAK Securities (lead)
Buyers: Cathal Friel (£250,000 subscription)
Insiders: Executive Chair Cathal Friel subscribed a further £250,000
Use of proceeds: Fund the POLB 001 TOPICAL trial and the oral GLP-1 proof-of-concept trial to completion; strengthen partnering position
Sep 29, 2026US$4.63M
Private placement of new ordinary shares
Made bigger: £4.87M · GBX 2.5 a share · Shore Capital +1
Dealers: Shore Capital (lead), Shore Capital Stockbrokers Limited (lead)
Buyers: Cathal Friel (4,000,000 new Ordinary Shares, investment of £100,000)
Insiders: Executive Chair Cathal Friel subscribed for 4,000,000 new Ordinary Shares, an investment of £100,000
Use of proceeds: Phase 2a trial of POLB 001 for cancer immunotherapy-induced CRS, oral GLP-1 proof-of-concept trial, cash runway into 2027
Jun 23, 2025US$6.56M
BookBuild Offer Shares (new ordinary shares)
Made bigger: £150,000 · GBX 2.5 a share · Shore Capital +1
Dealers: Shore Capital (lead), Shore Capital Stockbrokers Limited
Use of proceeds: Fund POLB 001 Phase 2a trial and oral GLP-1 proof of concept trial, providing runway into 2027
May 22, 2025US$201,316

Read by 6ix AI from the company's releases